Skip to main content

Advertisement

Log in

Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Aims

Heart rate was proposed as an emergent cardiovascular (CV) risk factor. Previous studies have shown associations between increased heart rate and CV risk in various populations. We aimed to evaluate the prognostic relevance of heart rate in a large contemporaneous medically optimized cohort of patients with stable chronic CV disease.

Methods and results

In a post hoc analysis of the ONTARGET/TRANSCEND trials, we evaluated associations between baseline and average heart rate in trial with CV risk in 31, 531 patients followed for a median of 5 years. The primary outcome, major vascular events (MVE), was a composite of CV death, myocardial infarction (MI), stroke, and congestive heart failure (CHF). Pre-specified secondary outcomes included all-cause death and the individual components of the primary outcome. Associations between heart rate and outcomes were computed with heart rate as a continuous variable, baseline heart rate >70 vs ≤70 bpm, and across heart rate quintiles, adjusting for other markers of risk, beta-blocker and non-dihydropyridine calcium channel blocker use. For each 10 bpm increase in baseline and average heart rate, we observed a significant increase in risk of MVE, CV death, CHF and all-cause death. There was a continuous relationship between MVE and baseline and, more importantly, average in-trial heart rate, with no observed threshold. MVE, CV death, stroke, CHF, and all-cause death increased across heart rate quintiles. There was no association between MI and HR. Results were consistent in clinically relevant subgroups. There were modest but significant improvements in C-statistic and in statistical measures of model calibration for models that included heart rate for MVE, CV death, CHF and all-cause death.

Conclusions

This large study examined and quantitated associations between heart rate and CV events in a contemporary medically optimized population with stable CV disease. Resting and, in particular, in-trial average heart rate are independently associated with significant increases in CV events and all-cause death.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Palatini P, Julius S (2004) Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hyperten 26:637–644

    Article  CAS  Google Scholar 

  2. Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM, Lepper M, Schoenberger JA, Lindberg HA (1980) Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 112:736–749

    CAS  PubMed  Google Scholar 

  3. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA (1987) Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 113:1489–1494

    Article  CAS  PubMed  Google Scholar 

  4. Gillum RF, Makuc DM, Feldman JJ (1991) Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J 121:172–177

    Article  CAS  PubMed  Google Scholar 

  5. Gillman MW, Kannel WB, Belanger A, D’Agostino RB (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J 125:1148–1154

    Article  CAS  PubMed  Google Scholar 

  6. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O’Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J (2002) Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 162:2313–2321

    Article  PubMed  Google Scholar 

  7. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ (2008) Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trandolapril Study (INVEST). Eur Heart J 29:1327–1334

    Article  PubMed Central  PubMed  Google Scholar 

  8. Shaper AG, Wannamethee G, Macfarlane PW, Walker M (1993) Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. Br Heart J 70:49–55

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, For the GUSTO-I Investigators (1995) Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 91:1659–1668

    Article  CAS  PubMed  Google Scholar 

  10. Zuanetti G, Mantini L, Hernández-Bernal F, Barlera S, di Gregorio D, Latini R, Maggioni AP (1999) Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience. Eur Heart J 1(Suppl J):H52–H57

    Google Scholar 

  11. Diaz A, Bourassa MG, Guertin MC, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26:967–974

    Article  PubMed  Google Scholar 

  12. Ho JE, Bittner V, Demicco DA, Breazna A, Deedwania PC, Waters DD (2010) Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (data from the Treating to New Targets [TNT] Trial). Am J Cardiol 105:905–911

    Article  PubMed  Google Scholar 

  13. Bangalore S, Messerli FH, Ou FS, Tamis-Holland J, Palazzo A, Roe MT, Hong MK (2010) Peterson ED; CRUSADE Investigators. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 5:552–560

    Article  Google Scholar 

  14. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817–821

    Article  PubMed  Google Scholar 

  15. Böhm M, Swedberg K, Komajda M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, On behalf of the SHIFT investigators (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894

    Article  PubMed  Google Scholar 

  16. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117:2377–2387

    Article  CAS  PubMed  Google Scholar 

  17. Beere PA, Glagov S, Zarins CK (1984) Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226:180–182

    Article  CAS  PubMed  Google Scholar 

  18. Perski A, Hamsten A, Lindvall K, Theorell T (1988) Heart rate correlates with severity of coronary atherosclerosis in young post infarction patients. Am Heart J 116:1369–1373

    Article  CAS  PubMed  Google Scholar 

  19. ONTARGET Investigators, Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:154–159

    Google Scholar 

  20. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372:1174–1183

    Article  CAS  PubMed  Google Scholar 

  21. Böhm M, Cotton D, Foster L, Custodis F, Laufs U, Sacco R, Bath PM, Yusuf S, Diener HC (2012) Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J 33:2804–2812

    Article  PubMed  Google Scholar 

  22. Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U (2010) Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 56:1973–1983

    Article  PubMed  Google Scholar 

  23. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11–19

    Article  PubMed  Google Scholar 

  24. Heidland UE, Strauer BE (2001) Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104:1477–1482

    Article  CAS  PubMed  Google Scholar 

  25. Palatini P, Casiglia E, Julius S, Pessina AC (1999) High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 159:585–592

    Article  CAS  PubMed  Google Scholar 

  26. Palatini P, Dorigatti F, Zaetta V, Mormino P, Mazzer A, Bortolazzi A, D’Este D, Pegoraro F, Milani L, Mos L, HARVEST Study Group (2006) Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens 24:1873–1880

    Article  CAS  PubMed  Google Scholar 

  27. Vergnaud AC, Protogerou AD, Li Y, Czernichow S, Vesin C, Blacher J, Safar ME (2008) Pulse pressure amplification, adiposity and metabolic syndrome in subjects under chronic antihypertensive therapy: the role of heart rate. Atherosclerosis 199:222–229

    Article  CAS  PubMed  Google Scholar 

  28. Lohse MJ, Engelhardt S, Danner S, Böhm M (1996) Mechanisms of beta-adrenergic receptor desensitization: from molecular biology to heart failure. Basic Res Cardiol 91(suppl 2):29–34

    Article  CAS  PubMed  Google Scholar 

  29. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885

    Article  CAS  PubMed  Google Scholar 

  30. Snappin S, Iglewicz B (2005) Illustrating the impact of a time-varying covariate with an extended Kaplan–Meier indicator. Am Stat 59:301–307

    Article  Google Scholar 

  31. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Yusuf S, Heart Outcomes Prevention Evaluation (HOPE) Investigators (2001) Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615–1621

    Article  CAS  PubMed  Google Scholar 

  32. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S, ONTARGET investigators (2009) Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27(7):1360–1369

    Article  CAS  PubMed  Google Scholar 

  33. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408–2416

    Article  PubMed Central  PubMed  Google Scholar 

  34. Cook N (2008) Statistical evaluation of prognostic versus diagnostic models. Clin Chem 54:17–23

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

All authors obtained scientific support by Boehringer Ingelheim. The ONTARGET/TRANSCEND trial was sponsored by Boehringer Ingelheim.

Ethical standard statement

The study was performed according to the Declaration of Helsinki. The approval was given by the ethical committees of the study centers participating in the ONTARGET/TRANSCEND trial.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Böhm.

Additional information

For the ONTARGET/TRANSCEND Investigators. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique Identifier NCT 00153101.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lonn, E.M., Rambihar, S., Gao, P. et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol 103, 149–159 (2014). https://doi.org/10.1007/s00392-013-0644-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-013-0644-4

Keywords

Navigation